Glycine Cools Core Body Temperature to Signal Natural Sleep Onset

The Circadian Paradox of Falling Asleep Cold

Every evening as darkness falls, the human body orchestrates a thermal shift that most people experience without understanding its physiological purpose. Long before eyelids grow heavy, internal core body temperature begins a steady downward slide. In healthy adults following a typical diurnal rhythm, core body temperature drops by roughly one degree Celsius over the course of the late evening and early night, reaching its lowest point, or nadir, in the early hours of the morning, usually around four or five o'clock. This nocturnal cooling curve is not an incidental byproduct of physical inactivity. Rather, it is a primary physiological gatekeeper for sleep onset. The central nervous system uses the rate of internal heat loss as a decisive biological cue to initiate the transition from wakefulness into non-rapid eye movement (NREM) sleep.

When this thermoregulatory cooling curve is blunted or delayed, sleep onset suffers. Individuals who toss and turn in bed, frustrated by racing thoughts or physical restlessness, frequently report feeling hot, stuffy, or unable to find a comfortable temperature beneath the sheets. While many attribute this discomfort to ambient bedroom climate or mental stress, the underlying physiological bottleneck is often an inability to transfer thermal energy away from vital internal organs. The human body cannot cool its core simply by willing the temperature down. Thermal energy stored within the liver, heart, kidneys, and brain must be transported through the circulatory system to the external boundary of the skin, where it can radiate into the surrounding environment.

The biological radiator that accomplishes this cooling consists of the distal vascular beds, primarily located in the hairless skin of the hands and feet. In the late 1990s, chronobiologist Kurt Kräuchi and his colleagues in Switzerland demonstrated that the speed with which a person falls asleep correlates directly with what physiologists term the distal-to-proximal skin temperature gradient (DPG). When peripheral blood vessels in the hands and feet dilate, warm blood flows away from the core and into the dense capillary networks of the extremities. As warm blood floods the fingers and toes, skin temperature in those distal areas rises, while core internal temperature drops rapidly. In clinical sleep laboratories, the steepest rise in the distal-to-proximal temperature gradient consistently predicts the exact window of sleep onset latency.

This physiological reality presents a fascinating paradox that frequently confuses wellness consumers. Falling asleep does not occur because the whole body becomes uniformly cold; rather, it occurs because the extremities become noticeably warm while the internal core sheds its heat. In recent years, researchers investigating dietary amino acids discovered that a remarkably simple nutritional compound, glycine, directly engages this exact thermoregulatory cascade. By modulating specific neural pathways that govern autonomic tone and vascular resistance, supplemental glycine accelerates the outward movement of heat, lowering core body temperature and providing a non-sedating, biological signal that tells the central nervous system it is time to sleep.

The Simplest Amino Acid with an Unexpected Central Target

Glycine occupies a unique position in organic chemistry and human biochemistry. Possessing the chemical formula NH2-CH2-COOH, it is the smallest and structurally simplest of the twenty standard amino acids used to build proteins in living organisms. Unlike every other proteinogenic amino acid, glycine does not contain an asymmetric carbon atom in its molecular skeleton. Its side chain consists solely of a single hydrogen atom, rendering it achiral and incapable of existing in optical D- or L-stereoisomeric forms. Because the human liver and kidneys can synthesize glycine from other metabolic precursors, most notably the amino acid serine via the enzyme serine hydroxymethyltransferase, nutritional science traditionally categorized glycine as non-essential.

Despite its humble structural profile and non-essential classification, glycine participates in an astonishing array of critical metabolic pathways. It serves as an indispensable precursor for the cellular synthesis of glutathione, the primary intracellular antioxidant that protects mitochondria from oxidative stress. It provides the central nitrogen and carbon atoms needed to build the porphyrin ring of heme, which carries oxygen within hemoglobin. In the liver, glycine conjugates with bile acids to form glycocholic acid, enabling the emulsification and absorption of dietary lipids in the duodenum. Furthermore, because its microscopic side chain allows dense, tight helical packing, glycine accounts for approximately one out of every three amino acid residues in collagen, providing structural strength to human skin, cartilage, bone, and vascular walls.

Beyond these fundamental structural and metabolic duties, glycine operates within the central nervous system as a vital neurotransmitter with dual personalities. In the spinal cord and brainstem, glycine binds to strychnine-sensitive glycine receptors, which are ligand-gated chloride channels. When glycine binds to these receptors, chloride ions rush into post-synaptic neurons, hyperpolarizing the cell membrane and dampening neural excitability. This classical inhibitory action prevents motor neuron hyperactivity, regulates muscle tone, and coordinates reflexive movements.

However, in the forebrain, hippocampus, and cerebral cortex, glycine plays an entirely different role. It acts as an obligatory co-agonist at the N-methyl-D-aspartate (NMDA) receptor complex, an ionotropic glutamate receptor essential for synaptic plasticity, memory encoding, and cellular communication. Unlike the inhibitory receptors in the spinal cord, the glycine binding site on the NMDA receptor is strychnine-insensitive. For an NMDA receptor channel to open and permit calcium influx, it must bind both glutamate and glycine simultaneously. For decades, neuroscientists assumed that extracellular glycine levels in the brain remained consistently saturated, treating glycine merely as a passive cofactor in glutamatergic signaling.

That assumption began to shift when clinical and preclinical investigations examined what happens when humans ingest free-form glycine in gram-scale amounts before bed. Following oral ingestion, glycine is rapidly absorbed in the upper small intestine through high-affinity sodium-dependent neutral amino acid transporters, primarily the PAT1 and B0AT1 transport systems located on the brush border membrane of enterocytes. Free glycine enters hepatic portal circulation and raises plasma glycine concentrations within thirty to forty-five minutes. Crucially, circulating glycine crosses the blood-brain barrier through specialized neutral amino acid transport carriers located on brain capillary endothelial cells. Once inside the central nervous system, this supplemental influx does not trigger generalized, heavy sedation like synthetic sedative-hypnotic drugs. Instead, it interacts with targeted neural circuits responsible for circadian timing and thermal balance.

How the Suprachiasmatic Nucleus Senses Glycine

The biological breakthrough explaining how glycine promotes sleep without acting as a blunt central depressant emerged from a series of meticulous neurobiological studies led by Dr. Nobuhiro Kawai and his research team. Published in the journal Neuropsychopharmacology, their investigations sought to identify the precise anatomical region and molecular receptor responsible for the hypothermic and sleep-promoting actions of systemically administered glycine.

Using microinjections, neuropharmacological antagonists, and microdialysis techniques in animal models, the researchers tested various candidates within the brainstem, hypothalamus, and basal forebrain. Their search converged on the master circadian pacemaker of the mammalian brain: the suprachiasmatic nucleus (SCN), a bilateral cluster of thousands of specialized neurons situated in the anterior hypothalamus directly above the optic chiasm. The SCN is the central clock that coordinates roughly 24-hour rhythmic oscillations in gene expression, endocrine secretion, feeding behavior, and body temperature across the entire organism.

Kawai and colleagues discovered that the shell region of the suprachiasmatic nucleus contains a dense population of NMDA receptors that are remarkably sensitive to exogenous glycine availability. When glycine was infused directly into the SCN shell, it replicated the exact core temperature drop and sleep-facilitating effects observed after systemic, oral ingestion. Conversely, when the researchers administered specific NMDA receptor antagonists into the SCN, or chemically blocked the glycine-binding site on the NR1 subunit of the NMDA complex, the hypothermic effect of glycine was completely abolished. In contrast, blocking strychnine-sensitive inhibitory glycine receptors in the spinal cord produced no inhibition of the temperature drop, establishing definitively that the hypothermic action of glycine is driven by central NMDA receptor activation in the master circadian clock, rather than by classical motor inhibition in the spine.

To understand why activating NMDA receptors in the SCN lowers body temperature, one must look at how the master clock communicates with the autonomic nervous system. The SCN does not merely track time through light input from the retina; it actively drives physiological rhythms by sending efferent neural projections to the preoptic area of the hypothalamus, the dorsomedial hypothalamic nucleus, and the rostral ventrolateral medulla. These downstream hypothalamic and medullary regions control autonomic outflow to blood vessels throughout the body.

Under baseline wakeful conditions during the day, high sympathetic nervous system tone maintains moderate vasoconstriction in peripheral skin vessels, keeping blood circulating through the core and preserving metabolic heat. When evening arrives, the intrinsic molecular clockwork of the SCN naturally alters its firing rates, initiating a gradual reduction in sympathetic vasoconstrictor tone to peripheral tissues. By binding to NMDA receptors within the SCN shell, supplemental glycine acts as an acute pharmacological signal that amplifies and accelerates this circadian transition. It essentially prompts the SCN to send an immediate inhibitory message through sympathetic outflow tracts, instructing the peripheral vasculature to relax its grip and allow blood to flood the outer extremities.

Opening the Peripheral Floodgates for Thermal Release

The immediate physiological consequence of this central SCN signaling is profound cutaneous vasodilation. To measure this phenomenon accurately, researchers utilized infrared thermography, laser Doppler flowmetry, and precision skin thermistors placed across distinct anatomical zones. In human clinical trials and animal models alike, the administration of glycine produces a rapid, selective increase in surface temperature across the paws, hands, and feet, accompanied by a reciprocal, progressive drop in internal rectal or core temperature.

This vascular response depends upon the specialized architecture of acral skin. The palms of the hands, soles of the feet, and facial skin contain high densities of specialized vascular structures known as arteriovenous anastomoses (AVAs). Unlike standard capillary loops that primarily serve nutrient and oxygen delivery to local cells, arteriovenous anastomoses are low-resistance, direct muscular shunts that connect arterioles directly to venules. When arteriovenous anastomoses are open, they allow extraordinary volumes of blood to bypass the high-resistance capillary bed and surge through superficial venous plexuses sitting directly beneath the thin epidermis.

Arteriovenous anastomoses are densely innervated by sympathetic adrenergic nerve fibers that release norepinephrine to stimulate alpha-1 and alpha-2 adrenergic receptors on vascular smooth muscle cells, maintaining them in a constricted state during active daytime hours. When the SCN dials back this sympathetic outflow following glycine ingestion, the smooth muscle rings of the AVAs relax completely. Blood flow through the hands and feet can increase several-fold within twenty to thirty minutes. Because the skin of the hands and feet possesses a very high surface-area-to-volume ratio and lacks thick insulating subcutaneous adipose tissue, it acts as a highly efficient natural radiator. Heat from the warm core blood radiates outward into the ambient room air through convection, radiation, and insensible evaporation.

As thermal energy escapes through the extremities, the temperature of blood returning through the vena cava back to the heart and core circulation is measurably cooler. Over the course of the next sixty to ninety minutes, internal core temperature drops by approximately 0.5 to 1.0 degree Celsius below daytime baseline levels. Human subjects enrolled in glycine trials typically note that their hands and feet feel pleasantly warm to the touch, while they simultaneously experience a distinct sensation of physical heaviness and relaxation.

This specific sequence of vascular events highlights why supplemental glycine works with human biology rather than against it. Traditional sleep medications, such as z-drugs or benzodiazepines, do not promote peripheral heat dissipation. In fact, many synthetic hypnotics impair natural thermoregulatory reflexes or lower blood pressure indiscriminately without specifically engaging the circadian DPG response. Glycine, by contrast, targets the precise biological gateway that nature designed to usher the brain into restorative sleep: warming the extremities to cool the core.

Sleep Architecture Without the Sedative Hangover

The practical value of any sleep-supporting nutritional intervention depends not only on whether it helps a person fall asleep, but on how it influences the microscopic architecture of sleep cycles throughout the night. Sleep is not a uniform state of unconsciousness. It consists of highly organized cycles alternating between light non-rapid eye movement sleep (NREM stages N1 and N2), deep restorative slow-wave sleep (NREM stage N3), and rapid eye movement (REM) sleep, during which vivid dreaming, memory consolidation, and emotional processing occur.

Many conventional pharmaceutical sleep aids and over-the-counter sedatives, such as first-generation antihistamines like diphenhydramine, achieve rapid sedation by broadly blunting central neurotransmission. Diphenhydramine blocks central histamine H1 receptors, inducing drowsiness but severely altering normal sleep architecture. It suppresses deep slow-wave sleep and causes prolonged daytime cognitive impairment, dry mouth, and psychomotor sluggishness, often referred to as a "sedative hangover." Similarly, benzodiazepines and benzodiazepine-receptor agonists enhance GABA-A receptor signaling across broad cortical areas, which can induce unconsciousness rapidly but tends to fragment REM sleep and reduce the power of low-frequency delta waves in stage N3 slow-wave sleep.

Polysomnographic sleep studies evaluating oral glycine tell a markedly different story. In clinical research conducted by Yamadera, Inagawa, and colleagues, volunteers who experienced chronic dissatisfaction with their sleep quality were administered three grams of crystalline glycine or an identical-looking placebo thirty minutes before turning out the lights. Participants underwent continuous nocturnal polysomnography, recording electroencephalograms (EEG), electrooculograms (EOG), and electromyograms (EMG) across repeated baseline, treatment, and washout nights.

The polysomnography data revealed three critical outcomes. First, oral glycine significantly shortened sleep onset latency, reducing the elapsed time between lights out and the first appearance of continuous stage N2 sleep spindles. Second, glycine accelerated the transition into deep NREM slow-wave sleep, increasing the proportion of delta-wave sleep during the initial third of the night, when restorative growth hormone secretion and cellular repair are highest. Third, and perhaps most importantly, glycine left the duration, latency, and cyclical distribution of REM sleep completely intact. It did not suppress REM sleep, nor did it cause rebound insomnia or erratic awakening episodes during the latter half of the night.

The subjective and cognitive evaluations following these sleep studies confirmed what the objective EEG recordings demonstrated. When participants awoke in the morning, their subjective sleep quality scores showed significant improvements: they reported feeling more refreshed, having an easier time waking up, and experiencing less daytime sleepiness. When subjected to standardized computer-based psychomotor vigilance tasks, continuous performance tests, and memory recall assessments the morning after taking glycine, subjects demonstrated preserved reaction times and cognitive accuracy, with zero evidence of the motor uncoordination, cognitive fog, or lethargy commonly seen with pharmacological sedatives.

Exogenous glycine promotes sleep via peripheral vasodilatation through the activation of NMDA receptors in the suprachiasmatic nucleus shell, naturally lowering core temperature to facilitate the transition into deep rest. — Dr. Nobuhiro Kawai

This preservation of daytime mental clarity makes neurobiological sense. Because glycine does not act as a central depressant or direct GABA-A receptor positive allosteric modulator, it does not leave lingering sedative residues that sedate the cerebral cortex after sunrise. Once the liver and peripheral tissues metabolize the supplemental amino acid, its primary physiological duty, accelerating the evening drop in core body temperature, has already been completed. The body continues its normal nocturnal sleep cycle guided by its own endogenous homeostatic and circadian drives.

Whole Food Matrices Versus Crystalline Glycine

As awareness of glycine's benefits for sleep and recovery has grown, many health-conscious consumers have begun asking whether they can obtain equivalent benefits simply by consuming glycine-rich whole foods before bed. Glycine is abundant throughout the natural food supply, particularly in animal proteins rich in connective tissue. Traditional dietary staples such as slow-simmered bone broth, braised meats, chicken skin, gelatin desserts, and modern dietary collagen peptide powders provide substantial amounts of glycine. In pure collagen protein, glycine makes up approximately 30 to 33 percent of all amino acid residues by molar ratio, meaning a ten-gram scoop of hydrolyzed collagen peptides delivers roughly three grams of glycine.

However, from the standpoint of clinical pharmacokinetics and circadian timing, consuming glycine as part of a complex whole-food matrix or intact protein is fundamentally different from drinking free, crystalline glycine dissolved in water. To understand why, one must follow the distinct digestive pathways of intact proteins versus free amino acids through the gastrointestinal tract.

When an individual consumes bone broth, gelatin, or unhydrolyzed collagen, the stomach must first secrete hydrochloric acid and the endopeptidase enzyme pepsin to denature the protein's dense tertiary and quaternary structures. In the acidic environment of the gastric lumen, pepsin cleaves large polypeptide chains into smaller oligopeptide fragments. These fragments pass into the duodenum, where pancreatic proteases, including trypsin, chymotrypsin, and elastase, break them down further into tripeptides, dipeptides, and single amino acids. Finally, brush border peptidases on the enterocyte surface complete the breakdown so that free amino acids can be absorbed via PAT1 and B0AT1 transporters, while di- and tripeptides enter enterocytes through the PEPT1 transporter.

This multi-stage digestive process requires substantial time, gastric motility, and enzymatic effort. When dietary protein is ingested in the evening, gastric emptying takes anywhere from one to three hours, depending on the presence of accompanying dietary fats, carbohydrates, and moisture. Consequently, plasma concentrations of glycine rise slowly and gradually over an extended multi-hour plateau. Furthermore, whole-food protein sources contain an array of other large neutral amino acids, including leucine, isoleucine, valine, phenylalanine, tyrosine, and tryptophan. These amino acids compete with one another for shared transport carriers across the intestinal epithelium and, more importantly, across the blood-brain barrier via the large neutral amino acid transporter 1 (LAT1).

In stark contrast, when a person consumes three grams of pure, crystalline glycine powder dissolved in room-temperature or warm water on an empty stomach, the digestive requirement is virtually zero. Because crystalline glycine is already a free monomeric amino acid, it requires no gastric breakdown, no enzymatic cleavage by pepsin or trypsin, and no prolonged residence in the stomach. Gastric emptying occurs within ten to fifteen minutes. The free glycine molecules enter the proximal duodenum and upper jejunum, where enterocyte apical transporters absorb them rapidly and completely into mesenteric capillaries.

Pharmacokinetic studies demonstrate that oral crystalline glycine produces a sharp, robust peak in plasma glycine concentration within thirty to forty-five minutes after ingestion. This acute, synchronized surge in circulating glycine is precisely what is needed to reach the capillary beds of the blood-brain barrier, cross into the hypothalamus, and saturate the NMDA receptor glycine-binding sites in the shell of the suprachiasmatic nucleus. The SCN receives an unmistakable pharmacological signal to immediately inhibit sympathetic vasoconstrictor tone in the extremities. A slow, trickle-like absorption of glycine from a heavy evening bowl of bone broth or an unhydrolyzed gelatin snack cannot produce this synchronized vascular response. In fact, consuming a heavy, rich broth late at night may inadvertently stimulate gastric thermogenesis and metabolic digestion, elevating core body temperature and working against the very sleep onset signal the person is trying to cultivate.

Hydrolyzed collagen peptide powders occupy an intermediate ground. Because collagen peptides have already undergone partial enzymatic hydrolysis, they dissolve readily in liquids and empty from the stomach faster than unhydrolyzed gelatin. A ten-gram serving of hydrolyzed collagen will certainly contribute to the body's overall pool of amino acids for connective tissue repair, joint health, and endogenous glutathione synthesis. However, for individuals whose primary goal is targeted, predictable sleep onset support, three grams of pure crystalline glycine remains the exact compound and delivery format validated in human clinical trials.

Dosage Parameters, Timing Windows, and Practical Boundaries

Translating the clinical research on glycine into an effective, sustainable evening routine requires careful attention to dosage, timing, and individual physiological factors. Fortunately, the human clinical trials conducted to date demonstrate remarkable consistency in both dosing protocols and timing windows.

Across the published double-blind, placebo-controlled trials, the universal evidence-based dosage for sleep latency and sleep quality improvement is exactly three grams of pure glycine. In human subjects, doses lower than three grams, such as one or two grams, have shown less reliable effects on distal vasodilation and sleep architecture. Conversely, escalating the dose to five, ten, or fifteen grams does not appear to provide proportional increases in sleep quality or core temperature reduction. Because the glycine-binding site on SCN NMDA receptors and the neutral amino acid transporters at the blood-brain barrier exhibit saturable binding kinetics, three grams provides sufficient systemic substrate to achieve maximal receptor occupancy without overwhelming peripheral clearance mechanisms.

Clinical protocols emphasize four practical administration parameters: - Evidence-based dose: Exactly three grams of pure crystalline glycine dissolved in water, providing optimal receptor saturation without overwhelming metabolic clearance pathways. - Target timing window: Ingestion thirty to sixty minutes before lights out to synchronize peak plasma concentrations with the body's natural circadian readiness. - Delivery format: Free-form powder in room-temperature water or non-caffeinated herbal infusion to ensure rapid gastric emptying and unhindered transport across the blood-brain barrier. - Individual boundaries: Professional medical consultation for individuals who are pregnant, nursing, taking central nervous system medications, or managing chronic renal or hepatic conditions.

The optimal timing window for taking glycine is between thirty and sixty minutes before the intended time of turning out the lights. This timing directly aligns with the compound's absorption and pharmacokinetic profile. Ingesting glycine thirty to sixty minutes before bed allows the amino acid to clear the stomach, enter systemic circulation, reach peak plasma levels, and initiate distal vasodilation in the hands and feet just as the person prepares to lay down. Taking glycine hours too early dissipates heat before the person is ready for bed, while taking it immediately before closing one's eyes means the cooling curve will lag behind the desire to sleep, potentially leaving the person feeling temporarily restless while the vascular transition gets underway.

In terms of administration, pure glycine powder is exceptionally user-friendly. It is a white crystalline powder that is highly soluble in water, tea, or non-caffeinated herbal infusions. Glycine possesses a naturally sweet taste, derived from the Greek word glykys, meaning sweet, with approximately sixty to seventy percent of the sweetness of sucrose. Despite its sweet flavor profile, glycine does not cause a sharp glycemic surge or trigger significant insulin secretion when consumed on its own, making it suitable for evening consumption without disrupting metabolic blood sugar control.

From a safety and tolerability perspective, glycine is one of the most thoroughly investigated and benign amino acids in human clinical nutrition. Clinical safety trials in humans have evaluated glycine at doses up to fifteen to thirty grams daily for weeks at a time in psychiatric and metabolic research, reporting minimal adverse effects beyond occasional mild, transient gastrointestinal softness or nausea at very high intakes. At the standard three-gram bedtime dose, gastrointestinal side effects are exceedingly rare, and subjects report no daytime dependency, tolerance, or withdrawal symptoms upon cessation.

Nevertheless, responsible wellness communication requires understanding the limits of dietary supplementation. Supplements are nutritional compounds designed to support normal biological function; they are not pharmaceuticals and cannot diagnose, treat, prevent, or cure medical sleep disorders. Chronic, debilitating insomnia that persists for months, loud gasping or snoring indicative of obstructive sleep apnea, restless legs syndrome, and severe circadian rhythm sleep-wake disorders require thorough medical evaluation by a qualified healthcare professional, not self-directed supplement stacking.

Furthermore, specific populations must exercise tailored caution. Women who are pregnant or breastfeeding should always consult their obstetrician or healthcare provider before introducing standalone amino acid supplements, as clinical safety trials are traditionally limited in these cohorts. Individuals with severe chronic kidney disease or advanced hepatic failure must carefully monitor their total dietary amino acid and nitrogen intake with their nephrologist or hepatologist, as impaired renal or hepatic clearance can alter amino acid metabolism. Additionally, individuals taking neuropsychiatric medications that modulate NMDA receptors, glutamate transmission, or central nervous system tone should discuss glycine supplementation with their prescribing physician to ensure safe pharmacological alignment.

Practical Habits to Amplify the Thermal Sleep Signal

While a three-gram serving of glycine provides a targeted biological catalyst for peripheral vasodilation, its effectiveness can be dramatically amplified or quietly undermined by the surrounding sleep environment. Because glycine works by shedding core heat through the skin of the extremities, ambient bedroom climate and nighttime behavioral habits directly influence how successfully that thermal transfer occurs.

The first and most critical environmental factor is ambient room temperature. Sleep physiology research consistently identifies the ideal bedroom ambient temperature for adult humans as being between 16 and 19 degrees Celsius (60 to 67 degrees Fahrenheit). If a bedroom is kept excessively warm, above 22 or 23 degrees Celsius, the thermal gradient between the dilated skin of the hands and feet and the ambient room air becomes narrow. Heat cannot radiate away from the skin efficiently, causing core body temperature to remain elevated despite maximum vasodilation. Conversely, if the room is appropriately cool, the thermal gradient remains steep, allowing heat to dissipate rapidly into the environment.

Bedding materials and sleepwear also play an instrumental role. Synthetic fabrics such as polyester and nylon trap moisture and heat, creating a microclimate around the body that prevents convective and evaporative cooling. In contrast, breathable, natural fibers like cotton, linen, or bamboo allow air circulation and wick away insensible perspiration. For individuals who frequently experience cold feet at night, wearing loose, breathable bed socks can actually accelerate sleep onset. While putting on socks might sound counterintuitive when the goal is to cool down, warming the feet externally dilates distal arteriovenous anastomoses, drawing warm blood from the core to the skin surface where it can dissipate through the rest of the body.

Another powerful behavioral synergy is the well-documented "warm bath effect," sometimes called the hot bath paradox. Taking a warm shower or soaking in a bath at approximately 40 to 42 degrees Celsius for ten to fifteen minutes about ninety minutes before bedtime significantly increases blood flow to the skin. When a person steps out of the warm water into a cooler room, cutaneous blood vessels remain wide open, triggering a rapid, precipitous drop in core body temperature that mirrors and amplifies the exact vascular effect induced by glycine.

Finally, light exposure in the evening remains the master regulator of the suprachiasmatic nucleus. While glycine acts as a chemical signal at NMDA receptors in the SCN shell, bright blue-enriched light from overhead fluorescent fixtures, computer monitors, and smartphone screens acts through melanopsin-containing retinal ganglion cells to stimulate daytime firing patterns in the SCN core. Exposing the eyes to bright light late at night stimulates sympathetic tone, fighting directly against the vasodilatory instructions that glycine is attempting to send. Dimming domestic lighting and minimizing screen exposure in the hour before bed creates a coherent, harmonious environment where visual cues and nutritional biochemistry work together, guiding the human body into natural, restorative sleep.

Sources: Neuropsychopharmacology (PMC4397399); Nature (PMID 10485703); Frontiers in Neurology (PMC3328957); Sleep and Biological Rhythms (DOI 10.1111/j.1479-8425.2007.00262.x); Sleep and Biological Rhythms (DOI 10.1111/j.1479-8425.2006.00193.x); New Zealand Ministry of Health Eating and Activity Guidelines.

Sources

pmc.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

www.health.govt.nz

This article is for general education and does not replace advice from a qualified healthcare professional.